Add like
Add dislike
Add to saved papers

Downregulation of ILT4 + dendritic cells in recurrent miscarriage and recurrent implantation failure.

PROBLEM: The role of ILT4+ DCs in healthy fertile controls and patients with recurrent miscarriages (RM) and recurrent implantation failure (RIF) is unclear.

METHOD OF STUDY: We studied the expression of ILT4 from peripheral blood and endometrial samples from healthy controls and patients with RM and RIF by flow cytometry and immunohistochemistry analysis. Endometrial Foxp3 expression was also investigated using immunohistochemistry.

RESULTS: In peripheral blood, there was a significant increase in the percentage of ILT4+ DCs in healthy fertile controls compared with patients with RM and RIF. The presence of ILT4+ DC is even more prominent in the endometrium of healthy fertile controls compared with patients with RM and RIF. Moreover, there was a strong correlation between the number of ILT4+ cells and Foxp3+ Tregs in healthy fertile controls, but not in patients with RM and RIF.

CONCLUSION: Our data indicate that ILT4+ DCs play an important role in the maintenance of immune tolerance during pregnancy, probably through the induction of Foxp3+ Treg cells, a process which is impaired in RM and RIF.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

Related Resources

For the best experience, use the Read mobile app

Mobile app image

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our terms of use and privacy policy.

Your Privacy Choices Toggle icon

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app